Biomarkers are associated with clinical and endoscopic outcomes with vedolizumab treatment in Crohn’...
Biomarkers are associated with clinical and endoscopic outcomes with vedolizumab treatment in Crohn’s disease
About this item
Full title
Author / Creator
Publisher
London, England: SAGE Publications
Journal title
Language
English
Formats
Publication information
Publisher
London, England: SAGE Publications
Subjects
More information
Scope and Contents
Contents
Background:
Vedolizumab, an α4β7 integrin antagonist, is an effective therapy for Crohn’s disease (CD). Biomarkers are needed to guide therapy and predict outcomes. This study evaluated biomarker concentrations and outcomes in patients with CD undergoing vedolizumab treatment.
Methods:
Sera at weeks 0, 2, 6, 14, and ⩾26 were collected from...
Alternative Titles
Full title
Biomarkers are associated with clinical and endoscopic outcomes with vedolizumab treatment in Crohn’s disease
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_32074c3c698f4ce585b75de0bf57a892
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_32074c3c698f4ce585b75de0bf57a892
Other Identifiers
ISSN
1756-2848,1756-283X
E-ISSN
1756-2848
DOI
10.1177/1756284820971214
